Cyclosporine
- Generic Name
- Cyclosporine
- Brand Names
- Cequa, Gengraf, Neoral, Restasis, Sandimmune, Verkazia, Vevye, Ikervis
- Drug Type
- Small Molecule
- Chemical Formula
- C62H111N11O12
- CAS Number
- 59865-13-3
- Unique Ingredient Identifier
- 83HN0GTJ6D
- Background
Cyclosporine is a calcineurin inhibitor known for its immunomodulatory properties that prevent organ transplant rejection and treat various inflammatory and autoimmune conditions. It is isolated from the fungus Beauveria nivea. Initially manufactured by Sandoz and approved for use by the FDA in 1983, cyclosporine is now available in various products by Novar...
- Indication
Cyclosporine is approved for a variety of conditions. Firstly, it is approved for the prophylaxis of organ rejection in allogeneic kidney, liver, and heart transplants. It is also used to prevent bone marrow transplant rejection. For the above indications, cyclosporine can be used in conjunction with azathioprine and corticosteroids. Finally, cyclosporine ca...
- Associated Conditions
- Atopic Dermatitis, Bone Marrow Transplant Rejection, Chronic transplant rejection, Connective Tissue Disorders, Dry Eyes, Graft-versus-host Disease (GVHD), Heart Transplant Rejection, Immune Thrombocytopenia (ITP), Interstitial Cystitis, Juvenile Idiopathic Arthritis (JIA), Kidney Transplant Rejection, Liver Transplant Rejection, Lupus Nephritis, Nephrotic Syndrome, Ocular Rosacea, Rheumatoid Arthritis, Severe Ulcerative Colitis, Steroid Dependent Nephrotic Syndrome, Steroid Resistant Nephrotic Syndrome, Uveitis, Vernal Keratoconjunctivitis, Blistering disorder, Refractory Ulcerative colitis, Severe Psoriasis, Severe, active Rheumatoid arthritis, Severe, recalcitrant Plaque psoriasis, Suppressed tear production
- Associated Therapies
- -
Pentostatin Followed by Peripheral Stem Cell Transplantation in Treating Patients With Advanced Kidney Cancer
- Conditions
- First Posted Date
- 2003-06-27
- Last Posted Date
- 2013-01-08
- Lead Sponsor
- Jonsson Comprehensive Cancer Center
- Target Recruit Count
- 4
- Registration Number
- NCT00006968
- Locations
- 🇺🇸
Jonsson Comprehensive Cancer Center, UCLA, Los Angeles, California, United States
Comparison of Biological Therapies Following Combination Chemotherapy and Bone Marrow or Peripheral Stem Cell Transplantation in Women With Stage II or Stage III Breast Cancer
- Conditions
- First Posted Date
- 2003-06-05
- Last Posted Date
- 2013-02-04
- Lead Sponsor
- Herbert Irving Comprehensive Cancer Center
- Registration Number
- NCT00008203
- Locations
- 🇺🇸
Herbert Irving Comprehensive Cancer Center, New York, New York, United States
Monoclonal Antibody Therapy, Chemotherapy, and Peripheral Stem Cell Transplantation in Treating Patients With Refractory Non-Hodgkin's Lymphoma
- Conditions
- First Posted Date
- 2003-06-02
- Last Posted Date
- 2013-08-07
- Lead Sponsor
- University of California, Davis
- Registration Number
- NCT00008021
- Locations
- 🇺🇸
University of California Davis Cancer Center, Sacramento, California, United States
Bone Marrow and Peripheral Stem Cell Transplantation in Treating Patients With Hematologic Cancer
- First Posted Date
- 2003-05-09
- Last Posted Date
- 2012-06-01
- Lead Sponsor
- Northwestern University
- Registration Number
- NCT00004232
- Locations
- 🇺🇸
Robert H. Lurie Comprehensive Cancer Center, Northwestern University, Chicago, Illinois, United States
Fludarabine Phosphate and Total-Body Irradiation Before Donor Peripheral Blood Stem Cell Transplant in Treating Patients With Chronic Lymphocytic Leukemia or Small Lymphocytic Leukemia
- Conditions
- Interventions
- First Posted Date
- 2003-05-07
- Last Posted Date
- 2017-12-08
- Lead Sponsor
- Fred Hutchinson Cancer Center
- Target Recruit Count
- 21
- Registration Number
- NCT00060424
- Locations
- 🇺🇸
Veterans Administration Center-Seattle, Seattle, Washington, United States
🇮🇹University of Torino, Torino, Italy
🇺🇸Fred Hutchinson Cancer Research Center/University of Washington Cancer Consortium, Seattle, Washington, United States
Allogeneic Stem Cell Transplant in Treating Patients With Metastatic Kidney Cancer
- First Posted Date
- 2003-03-07
- Last Posted Date
- 2021-02-24
- Lead Sponsor
- UNICANCER
- Target Recruit Count
- 57
- Registration Number
- NCT00056095
- Locations
- 🇫🇷
Centre Paul Papin, Angers, France
🇫🇷Centre Hospitalier Regional de Besancon - Hopital Jean Minjoz, Besancon, France
🇫🇷Centre Hospitalier Regional et Universitaire d'Angers, Angers, France
Donor Umbilical Cord Blood Transplantation in Treating Patients With Leukemia, Lymphoma, or Nonmalignant Hematologic Disorders
- Conditions
- First Posted Date
- 2003-03-07
- Last Posted Date
- 2011-03-07
- Lead Sponsor
- Roswell Park Cancer Institute
- Registration Number
- NCT00055653
- Locations
- 🇺🇸
Children's Hospital Los Angeles, Los Angeles, California, United States
🇺🇸Children's Hospital of Orange County, Orange, California, United States
🇺🇸North Shore University Hospital, Manhasset, New York, United States
Reduced-Intensity Conditioning Followed By Donor Peripheral Blood Stem Cell Transplant in Treating Patients With Multiple Myeloma
- Conditions
- Interventions
- First Posted Date
- 2003-02-06
- Last Posted Date
- 2017-10-16
- Lead Sponsor
- Fred Hutchinson Cancer Center
- Target Recruit Count
- 16
- Registration Number
- NCT00054353
- Locations
- 🇮🇹
University of Torino, Torino, Italy
🇺🇸Fred Hutchinson Cancer Research Center/University of Washington Cancer Consortium, Seattle, Washington, United States
Combination Chemotherapy and Antithymocyte Globulin in Reducing Graft-Versus-Host Disease in Patients Undergoing Donor Stem Cell Transplantation For Myelodysplastic Syndrome or Myeloproliferative Disorder
- First Posted Date
- 2003-02-06
- Last Posted Date
- 2010-05-14
- Lead Sponsor
- Fred Hutchinson Cancer Center
- Registration Number
- NCT00054340
- Locations
- 🇺🇸
Fred Hutchinson Cancer Research Center, Seattle, Washington, United States
S0125, Chemotherapy, Total-Body Irradiation, and Peripheral Stem Cell Transplantation in Treating Older Patients With Acute Myeloid Leukemia
- First Posted Date
- 2003-01-28
- Last Posted Date
- 2015-03-25
- Lead Sponsor
- SWOG Cancer Research Network
- Target Recruit Count
- 5
- Registration Number
- NCT00053014
- Locations
- 🇺🇸
CCOP - Atlanta Regional, Atlanta, Georgia, United States
🇺🇸University of Mississippi Medical Center, Jackson, Mississippi, United States
🇺🇸USC/Norris Comprehensive Cancer Center and Hospital, Los Angeles, California, United States
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.